Skip to main content

Early Hydroxychloroquine Slows Cutaneous Lupus Progression A prospective study of patients with limited cutaneous lupu

Social Author Name
Dr. John Cush
Tweet Content
Early Hydroxychloroquine Slows Cutaneous Lupus Progression A prospective study of patients with limited cutaneous lupus erythematosus (CLE) shows that early introduction of hydroxychloroquine (HCQ) may prevent progression to systemic lupus erythematosus (SLE).… https://t.co/cxz4DJ6AUs https://t.co/FlgwykFnfl

Bimekizumab efficacy and safety in patients with psoriatic arthritis who had skin and nail psoriasis at baseline: Up to

Social Author Name
Dr. John Cush
Tweet Content
Bimekizumab efficacy and safety in patients with psoriatic arthritis who had skin and nail psoriasis at baseline: Up to 2-year results from two phase 3 studies https://t.co/RZSwrj8as8
Crohn’s Microbiome may Predispose to Axial Spondyloarthritis

People with Crohn’s disease and related joint inflammation linked to immune system dysfunction have distinct gut bacteria or microbiota, with the bacterium Mediterraneibacter gnavus being a potential biomarker, according to new study by Weill Cornell Medicine researchers.

RheumNow Live 2025 is now available On Demand For the first time, https://t.co/4UQlqwujiR is offering exclusive access

Social Author Name
Dr. John Cush
Tweet Content
RheumNow Live 2025 is now available On Demand For the first time, https://t.co/4UQlqwujiR is offering exclusive access to: ✅ 7 STEP Talks from top rheumatology experts ✅ 21 Powerful lectures and Q & A Panels answering real-world questions ✅ All speaker slides and handouts… https://t.co/HokIfxbgTd https://t.co/ztVymFLuRT

From Bellyache to Bloodstorm - a Mesenteric Sclerosis case with Macrophage Activation Syndrome Presentation by Dr. Anj

Social Author Name
Dr. John Cush
Tweet Content
From Bellyache to Bloodstorm - a Mesenteric Sclerosis case with Macrophage Activation Syndrome Presentation by Dr. Anjali Nidhaan at the Rheumatology Winter Clinical Symposia - Feb 2025 https://t.co/pXwav5f2BI https://t.co/0Faao7zhbV
Normalizing Serologies Enhances Remission in SLE

Analysis of five phase III belimumab (BEL) trials reveals that normalizing serologies affords protection against severe and renal SLE flares, supporting the concept of treat-to-target to minimize risk in SLE.

Several measures of SLE outcomes (DORIS, Lupus Low Disease Activity State (LLDAS) include serological markers. This study examined the impact of achieving normal serum anti-dsDNA and complement levels on outcomes.

Full read review of Hydryoxychloroquine -its pharmacology, MOA (eg, blocking TLR 7 & 9), Dz specific efficacy and ad

Social Author Name
Dr. John Cush
Tweet Content
Full read review of Hydryoxychloroquine -its pharmacology, MOA (eg, blocking TLR 7 & 9), Dz specific efficacy and adverse effects https://t.co/WVErW1RrCj https://t.co/eQVFIZNSRx
Intraarticular Steroids in OA Lowers Need for Pain Meds

Is it possible that intra-articular corticosteroid injections for osteoarthritis might affect the use of opioids?

British patients with osteoarthritis (OA) who received intra-articular corticosteroid injections had less usage of opioid-containing drugs and other painkillers for years afterward, researchers said.

Bubble Trouble - When Bullous Lupus Bursts onto the SLE Scene Presentation by Dr. Alana Haussmann at the Rheumatology

Social Author Name
Dr. John Cush
Tweet Content
Bubble Trouble - When Bullous Lupus Bursts onto the SLE Scene Presentation by Dr. Alana Haussmann at the Rheumatology Winter Clinical Symposia - Feb 2025 https://t.co/LRsT1TLEm4 https://t.co/bSi50pDn2O
Subscribe to
×